Syneos Health, a leading biopharmaceutical solutions organisation, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 2018 through the merger of INC Research and inVentiv Health, the company has quickly established itself as a key player in the clinical research and commercialisation sectors. Specialising in integrated biopharmaceutical solutions, Syneos Health offers a unique combination of clinical development and commercial services, enabling clients to navigate the complexities of drug development more effectively. Their innovative approach and commitment to delivering results have positioned them as a trusted partner for pharmaceutical and biotechnology companies. With a strong market presence, Syneos Health has achieved notable milestones, including recognition for its comprehensive service offerings and a focus on patient-centric solutions, making it a preferred choice in the competitive landscape of biopharmaceutical services.
How does Syneos Health's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Syneos Health's score of 65 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Syneos Health reported total carbon emissions of approximately 16,500,000 kg CO2e for Scope 1, 5,116,000 kg CO2e for Scope 2 (market-based), and significant Scope 3 emissions, including 172,500,000 kg CO2e from purchased goods and services and 36,888,000 kg CO2e from business travel. In 2023, the figures were slightly lower, with Scope 1 emissions at about 16,298,000 kg CO2e and Scope 2 emissions at 9,704,000 kg CO2e (market-based). Syneos Health has set ambitious climate commitments, including a target to reduce absolute Scope 1 and 2 emissions by 42% by 2030 from a 2023 baseline. Additionally, they aim to cut Scope 3 emissions from purchased goods and services and business travel by 25% within the same timeframe. The company is also a signatory of The Climate Pledge, committing to achieve net zero carbon emissions by 2040. These initiatives reflect Syneos Health's dedication to minimising its climate impact and align with industry standards for sustainability and emissions reduction.
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 16,298,000 | 00,000,000 |
| Scope 2 | 9,704,000 | 0,000,000 |
| Scope 3 | 261,804,000 | 000,000,000 |
Syneos Health's Scope 3 emissions, which decreased by 14% last year and decreased by approximately 14% since 2023, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 77% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Syneos Health has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Syneos Health's sustainability data and climate commitments